A Focus on IL-17 Targeting Treatments in Psoriasis

Fabre, Jean-Michel; Giustiniani, J閞鬽e; Antonicelli, Frank; Merrouche, Yacine; Bagot, Martine; Bensussan, Armand

doi:10.17554/j.issn.2413-8223.2016.01.10

Cited by 3 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the human genome sequencing achieved, 5 other members of the IL-17 family, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F were recognized using sequence homology [30]. These cytokines play roles in immunity, in infections [31], in tumor immunity [32], in inflammatory chronic disease [33,34], in autoimmunity [35,36,37], and in atherosclerosis [38]. IL-17F is the closest to IL-17A from a sequence point of view (55% homology), is secreted by the same cell types and the genes encoding these two cytokines are both located on chromosome 6 [39].…”

Section: The Il-17/il-17r Axismentioning

confidence: 99%

The Interleukin-17 Family of Cytokines in Breast Cancer

Fabre

Giustinniani

Garbar

et al. 2018

IJMS

Self Cite

View full text Add to dashboard Cite

Breast cancer (BC) is the most common cancer in women worldwide and remains a major cause of mortality with an expected 137,000 death this year in Europe. Standard management of metastatic BC comprises hormonotherapy, chemotherapy, and targeted therapies. Cyclin dependent kinase (CDK) and mammalian target of rapamycin (mTOR) inhibitors have recently proved their efficiency in hormonal receptor expressing BC. Checkpoint proteins inhibition is being evaluated in phase 3 studies. Since inflammation is constantly present in cancers, research teams have focused their attention on the interleukin-17 (IL-17) family of proinflammatory cytokines. Preclinical experiments have reported both pro and antitumor effects depending on the conditions. In the present article, we review the accumulating evidences about the roles of IL-17 in BC and discuss whether this family of cytokines could be a new target in anticancer treatments.

show abstract

Section: The Il-17/il-17r Axismentioning

confidence: 99%

The Interleukin-17 Family of Cytokines in Breast Cancer

Fabre

Giustinniani

Garbar

et al. 2018

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…If the efficacy of IL-17 pathway inhibiting therapies in inflammatory disease like rheumatoid arthritis or psoriasis has been clearly established [ 45 ], it still has to be validated as a target for cancer treatment given its double-edged role in cancer. Indeed, since its primary detection in human cancers including breast, gastric and prostate cancer [ 46 , 47 , 48 , 49 , 50 , 51 ], the role of IL-17 in oncology has been highly debated and controversial [ 52 ].…”

Section: The Il-17/il-17r Axismentioning

confidence: 99%

Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type

Fabre

Giustiniani

Garbar

et al. 2016

IJMS

Self Cite

115

View full text Add to dashboard Cite

The inflammatory process contributes to immune tolerance as well as to tumor progression and metastasis. By releasing extracellular signals, cancerous cells constantly shape their surrounding microenvironment through their interactions with infiltrating immune cells, stromal cells and components of extracellular matrix. Recently, the pro-inflammatory interleukin 17 (IL-17)-producing T helper lymphocytes, the Th17 cells, and the IL-17/IL-17 receptor (IL-17R) axis gained special attention. The IL-17 family comprises at least six members, IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also called IL-25), and IL-17F. Secreted as disulfide-linked homo- or heterodimers, the IL-17 bind to the IL-17R, a type I cell surface receptor, of which there are five variants, IL-17RA to IL-17RE. This review focuses on the current advances identifying the promoting role of IL-17 in carcinogenesis, tumor metastasis and resistance to chemotherapy of diverse solid cancers. While underscoring the IL-17/IL-17R axis as promising immunotherapeutic target in the context of cancer managing, this knowledge calls upon further in vitro and in vivo studies that would allow the development and implementation of novel strategies to combat tumors.

show abstract

“…The importance of the Th17 axis has been extensively studied and demonstrated in chronic inflammatory disease of the skin or the joints. Antibodies directed against IL-17 or IL-17R is clinically effective and has shown therapeutic responses never seen before in psoriasis [3]. Besides, several studies have reported IL-17 and IL-17R to play roles in diverse cancer types though some results are conflicting [4].…”

Section: Introductionmentioning

confidence: 99%